You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 3.89.0.0/16 has been blocked (disabled) by ‪L235‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider or colocation provider. To prevent abuse, web hosts and colocation providers may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host or colocation provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a colocation provider's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a colocation web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host or colocation provider (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host or colocation provider.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and requests should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 18:20, 24 March 2026.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis. The block was made by ‪Wiki13‬. The reason given is Open proxy/Webhost: Visit the FAQ if you are affected .
- Start of block: 13:43, 5 May 2022
- Expiry of block: 13:43, 5 May 2024
Your current IP address is 3.89.215.189. The blocked range is 3.89.0.0/16. Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

You can view and copy the source of this page:

{| class="wikitable sortable mw-collapsible (({state<includeonly>|mw-collapsed</includeonly>))}" style="font-size:small; margin: 1em auto;"
|+ class="nowrap" | ((Navbar|Pharmacokinetics of long-acting injectable antipsychotics|mini=y)) ((Font|size=105%|<noinclude>[[Pharmacokinetics]]</noinclude><includeonly>Pharmacokinetics</includeonly> of <noinclude>[[depot effect|long-acting]]</noinclude><includeonly>long-acting</includeonly> <noinclude>[[intramuscular injection|injectable]]</noinclude><includeonly>injectable</includeonly> <noinclude>[[antipsychotic]]s</noinclude><includeonly>antipsychotics</includeonly>))
|-
! Medication !! Brand name !! Class !! Vehicle !! Dosage !! T<sub>max</sub> !! t<sub>1/2</sub> single !! t<sub>1/2</sub> multiple !! logP<sup>c</sup> !! Ref
|-
| ((No selflink|Aripiprazole lauroxil)) || Aristada || ((No selflink|Atypical antipsychotic|Atypical)) || [[Water]]<sup>a</sup> || 441–1064&nbsp;mg/4–8&nbsp;weeks || 24–35&nbsp;days || ? || 54–57&nbsp;days || 7.9–10.0 || 
|-
| ((No selflink|Aripiprazole monohydrate)) || Abilify Maintena || ((No selflink|Atypical antipsychotic|Atypical)) || [[Water]]<sup>a</sup> || 300–400&nbsp;mg/4&nbsp;weeks || 7&nbsp;days || ? || 30–47&nbsp;days || 4.9–5.2 || 
|-
| ((No selflink|Bromperidol decanoate)) || Impromen Decanoas || ((No selflink|Typical antipsychotic|Typical)) || [[Sesame oil]] || 40–300&nbsp;mg/4&nbsp;weeks || 3–9&nbsp;days || ? || 21–25&nbsp;days || 7.9 || <ref name="ParentToussaint1983">((cite journal | vauthors = Parent M, Toussaint C, Gilson H | date = 1983 | title = Long-term treatment of chronic psychotics with bromperidol decanoate: clinical and pharmacokinetic evaluation. | journal = Current Therapeutic Research | volume = 34 | issue = 1 | pages = 1–6 ))</ref>
|-
| ((No selflink|Clopentixol decanoate)) || Sordinol Depot || ((No selflink|Typical antipsychotic|Typical)) || [[Viscoleo]]<sup>b</sup> || 50–600&nbsp;mg/1–4&nbsp;weeks || 4–7&nbsp;days || ? || 19&nbsp;days || 9.0 || <ref name="pmid6931472">((cite journal | vauthors = Jørgensen A, Overø KF | title = Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels | journal = Acta Psychiatrica Scandinavica. Supplementum | volume = 279 | pages = 41–54 | date = 1980 | pmid = 6931472 | doi = 10.1111/j.1600-0447.1980.tb07082.x ))</ref>
|-
| ((No selflink|Flupentixol decanoate)) || Depixol || ((No selflink|Typical antipsychotic|Typical)) || [[Viscoleo]]<sup>b</sup> || 10–200&nbsp;mg/2–4&nbsp;weeks || 4–10&nbsp;days || 8&nbsp;days || 17&nbsp;days || 7.2–9.2 || <ref name="pmid6931472" /><ref name="Reynolds1993">((cite book | vauthors = Reynolds JE | date = 1993 | chapter = Anxiolytic sedatives, hypnotics and neuroleptics. | title = Martindale: The Extra Pharmacopoeia | edition = 30th | pages = 364–623 | publisher = Pharmaceutical Press | location = London ))</ref>
|-
| ((No selflink|Fluphenazine decanoate)) || Prolixin Decanoate || ((No selflink|Typical antipsychotic|Typical)) || [[Sesame oil]] || 12.5–100&nbsp;mg/2–5&nbsp;weeks || 1–2&nbsp;days || 1–10&nbsp;days || 14–100&nbsp;days || 7.2–9.0 || <ref name="pmid6143748">((cite journal | vauthors = Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR | title = Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches | journal = The Journal of Clinical Psychiatry | volume = 45 | issue = 5 Pt 2 | pages = 50–9 | date = May 1984 | pmid = 6143748 ))</ref><ref name="pmid444352">((cite journal | vauthors = Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA | title = Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man | journal = British Journal of Clinical Pharmacology | volume = 7 | issue = 4 | pages = 325–31 | date = April 1979 | pmid = 444352 | pmc = 1429660 | doi = 10.1111/j.1365-2125.1979.tb00941.x ))</ref><ref name="YoungEreshefsky1984">((cite conference | vauthors = Young D, Ereshefsky L, Saklad SR, Jann MW, Garcia N | title = Explaining the pharmacokinetics of fluphenazine through computer simulations. (Abstract.) | conference = 19th Annual Midyear Clinical Meeting of the American Society of Hospital Pharmacists. | location = Dallas, Texas | date = 1984 ))</ref>
|-
| ((No selflink|Fluphenazine enanthate)) || Prolixin Enanthate || ((No selflink|Typical antipsychotic|Typical)) || [[Sesame oil]] || 12.5–100&nbsp;mg/1–4&nbsp;weeks || 2–3&nbsp;days || 4&nbsp;days || ? || 6.4–7.4 || <ref name="pmid444352" />
|-
| ((No selflink|Fluspirilene)) || Imap, Redeptin || ((No selflink|Typical antipsychotic|Typical)) || [[Water]]<sup>a</sup> || 2–12&nbsp;mg/1&nbsp;week || 1–8&nbsp;days || 7&nbsp;days || ? || 5.2–5.8 || <ref name="pmid4992598">((cite journal | vauthors = Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, van Nueten JM, Marsboom RH, Hérin VV, Schaper WK | title = The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug | journal = Arzneimittel-Forschung | volume = 20 | issue = 11 | pages = 1689–98 | date = November 1970 | pmid = 4992598 ))</ref>
|-
| ((No selflink|Haloperidol decanoate)) || Haldol Decanoate || ((No selflink|Typical antipsychotic|Typical)) || [[Sesame oil]] || 20–400&nbsp;mg/2–4&nbsp;weeks || 3–9&nbsp;days || colspan="2" | 18–21&nbsp;days || 7.2–7.9 || <ref name="pmid3545764">((cite journal | vauthors = Beresford R, Ward A | title = Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis | journal = Drugs | volume = 33 | issue = 1 | pages = 31–49 | date = January 1987 | pmid = 3545764 | doi = 10.2165/00003495-198733010-00002 ))</ref><ref name="pmid7185768">((cite journal | vauthors = Reyntigens AJ, Heykants JJ, Woestenborghs RJ, Gelders YG, Aerts TJ | title = Pharmacokinetics of haloperidol decanoate. A 2-year follow-up | journal = International Pharmacopsychiatry | volume = 17 | issue = 4 | pages = 238–46 | date = 1982 | pmid = 7185768 | doi = 10.1159/000468580 ))</ref>
|-
| ((No selflink|Olanzapine pamoate)) || Zyprexa Relprevv || ((No selflink|Atypical antipsychotic|Atypical)) || [[Water]]<sup>a</sup> || 150–405&nbsp;mg/2–4&nbsp;weeks || 7&nbsp;days || ? || 30&nbsp;days || – || 
|-
| ((No selflink|Oxyprothepin decanoate)) || Meclopin || ((No selflink|Typical antipsychotic|Typical)) || ? || ? || ? || ? || ? || 8.5–8.7 || 
|-
| ((No selflink|Paliperidone palmitate)) || Invega Sustenna || ((No selflink|Atypical antipsychotic|Atypical)) || [[Water]]<sup>a</sup> || 39–819&nbsp;mg/4–12&nbsp;weeks || 13–33&nbsp;days || 25–139&nbsp;days || ? || 8.1–10.1 || 
|-
| ((No selflink|Perphenazine decanoate)) || Trilafon Dekanoat || ((No selflink|Typical antipsychotic|Typical)) || [[Sesame oil]] || 50–200&nbsp;mg/2–4&nbsp;weeks || ? || ? || 27&nbsp;days || 8.9 || 
|-
| ((No selflink|Perphenazine enanthate)) || Trilafon Enanthate || ((No selflink|Typical antipsychotic|Typical)) || [[Sesame oil]] || 25–200&nbsp;mg/2&nbsp;weeks || 2–3&nbsp;days || ? || 4–7&nbsp;days || 6.4–7.2 || <ref name="LarssonAxelsson1984">((cite journal | vauthors = Larsson M, Axelsson R, Forsman A | title = On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate. | journal = Current Therapeutic Research | date = 1984 | volume = 36 | issue = 6 | pages = 1071–88  ))</ref>
|-
| ((No selflink|Pipotiazine palmitate)) || Piportil Longum || ((No selflink|Typical antipsychotic|Typical)) || [[Viscoleo]]<sup>b</sup> || 25–400&nbsp;mg/4&nbsp;weeks || 9–10&nbsp;days || ? || 14–21&nbsp;days || 8.5–11.6 || <ref name="Reynolds1993" />
|-
| ((No selflink|Pipotiazine undecylenate)) || Piportil Medium || ((No selflink|Typical antipsychotic|Typical)) || [[Sesame oil]] || 100–200&nbsp;mg/2&nbsp;weeks || ? || ? || ? || 8.4 || 
|-
| ((No selflink|Risperidone)) || Risperdal Consta || ((No selflink|Atypical antipsychotic|Atypical)) || [[Microsphere]]s || 12.5–75&nbsp;mg/2&nbsp;weeks || 21&nbsp;days || ? || 3–6&nbsp;days || – || 
|-
| ((No selflink|Zuclopentixol acetate)) || Clopixol Acuphase || ((No selflink|Typical antipsychotic|Typical)) || [[Viscoleo]]<sup>b</sup> || 50–200&nbsp;mg/1–3&nbsp;days || 1–2&nbsp;days || colspan="2" | 1–2 days<!--32–36 hours--> || 4.7–4.9 || 
|-
| ((No selflink|Zuclopentixol decanoate)) || Clopixol Depot || ((No selflink|Typical antipsychotic|Typical)) || [[Viscoleo]]<sup>b</sup> || 50–800&nbsp;mg/2–4&nbsp;weeks || 4–9&nbsp;days || ? || 11–21&nbsp;days || 7.5–9.0 || 
|- class="sortbottom"
| colspan="10" style="width: 1px; background-color:#eaecf0; background-color:#eaecf0; text-align: center;" | '''Note:''' All by [[intramuscular injection]]. '''Footnotes:''' <sup>a</sup> = [[Microcrystalline]] or [[nanocrystalline]] [[aqueous suspension]]. <sup>b</sup> = Low-[[viscosity]] [[vegetable oil]] (specifically [[fractionated coconut oil]] with [[medium-chain triglyceride]]s). <sup>c</sup> = Predicted, from [[PubChem]] and [[DrugBank]]. '''Sources:''' ''Main:'' <noinclude><ref name="pmid7520856">((cite journal | vauthors = Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L | title = Depot antipsychotic drugs. Place in therapy | journal = Drugs | volume = 47 | issue = 5 | pages = 741–73 | date = May 1994 | pmid = 7520856 | doi = 10.2165/00003495-199447050-00004 ))</ref><ref name="pmid2864156">((cite journal | vauthors = Jann MW, Ereshefsky L, Saklad SR | title = Clinical pharmacokinetics of the depot antipsychotics | journal = Clinical Pharmacokinetics | volume = 10 | issue = 4 | pages = 315–33 | date = 1985 | pmid = 2864156 | doi = 10.2165/00003088-198510040-00003 ))</ref><ref name="DenckerAxelsson1996">((cite journal| vauthors = Dencker SJ, Axelsson R |title=Optimising the Use of Depot Antipsychotics|journal=CNS Drugs|volume=6|issue=5|year=1996|pages=367–381 |doi=10.2165/00023210-199606050-00004))</ref><ref name="pmid26585875">((cite journal | vauthors = Lee LH, Choi C, Collier AC, Barr AM, Honer WG, Procyshyn RM | title = The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values | journal = CNS Drugs | volume = 29 | issue = 12 | pages = 975–83 | date = December 2015 | pmid = 26585875 | doi = 10.1007/s40263-015-0295-2 ))</ref><ref name="pmid23343447">((cite journal | vauthors = Spanarello S, La Ferla T | title = The pharmacokinetics of long-acting antipsychotic medications | journal = Current Clinical Pharmacology | volume = 9 | issue = 3 | pages = 310–7 | date = 2014 | pmid = 23343447 | doi = 10.2174/15748847113089990051 ))</ref><ref name="pmid29350127">((cite journal | vauthors = Meyer JM | title = Converting oral to long-acting injectable antipsychotics: a guide for the perplexed | journal = CNS Spectrums | volume = 22 | issue = S1 | pages = 14–28 | date = December 2017 | pmid = 29350127 | doi = 10.1017/S1092852917000840 ))</ref><ref name="Taylor2018">((cite journal| vauthors = Taylor D |title=Depot antipsychotics revisited|journal=Psychiatric Bulletin|volume=23|issue=9|year=2018|pages=551–553|issn=0955-6036 |doi=10.1192/pb.23.9.551 ))</ref><ref name="SteinWilkinson2007">((cite book| vauthors = Stein G, Wilkinson G |title=Seminars in General Adult Psychiatry|url=https://books.google.com/books?id=6PGzHFuS1xkC&pg=PA254|date=April 2007|publisher=RCPsych Publications|isbn=978-1-904671-44-2|pages=254–))</ref><ref name="GardnerMurphy2014">((cite journal| vauthors = Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ |title=International Consensus Study of Antipsychotic Dosing|journal=FOCUS|volume=12|issue=2|year=2014|pages=235–243|issn=1541-4094|doi=10.1176/appi.focus.12.2.235))</ref><ref name="M.Z.2019">((cite book| vauthors = Procyshyn RM, Bezchlibnyk-Butler KZ, Jeffries JJ |title=Clinical Handbook of Psychotropic Drugs|url=https://books.google.com/books?id=EzaaDwAAQBAJ&pg=PA137|date=15 May 2019|publisher=Hogrefe Verlag|isbn=978-1-61676-561-3|pages=137–))</ref><ref name="Kapfhammer1990">((cite book| vauthors = Kapfhammer HP |chapter=Umstellungsregime von Kurzzeit- auf Depotneuroleptika|trans-chapter=Changeover regime from short-term to depot neuroleptics|year=1990|pages=173–198|doi=10.1007/978-3-642-75194-3_18|title=Thioxanthene in der Neuroleptischen Behandlung|trans-title=Thioxanthenes in Neuroleptic Treatment))</ref><ref name="WrightBurgess2012">((cite book| vauthors = Wright JC, Burgess DJ |title=Long Acting Injections and Implants|url=https://books.google.com/books?id=36nkGjEGEToC&pg=PA114|date=29 January 2012|publisher=Springer Science & Business Media|isbn=978-1-4614-0554-2|pages=114–117))</ref></noinclude><includeonly>See template.</includeonly>
|}<!--

--><noinclude>((Documentation|content=
== References ==
((Reflist))
))
[[Category:Antipsychotics]]
[[Category:Antipsychotic esters]]
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Pages transcluded onto the current version of this page (help):

Aripiprazole lauroxil (edit)
Aripiprazole monohydrate (edit)
Atypical antipsychotic (edit)
Bromperidol decanoate (edit)
Clopentixol decanoate (edit)
Flupentixol decanoate (edit)
Fluphenazine decanoate (edit)
Fluphenazine enanthate (edit)
Fluspirilene (edit)
Haloperidol decanoate (edit)
Olanzapine pamoate (edit)
Oxyprothepin decanoate (edit)
Paliperidone palmitate (edit)
Perphenazine decanoate (edit)
Perphenazine enanthate (edit)
Pipotiazine palmitate (edit)
Pipotiazine undecylenate (edit)
Risperidone (edit)
Typical antipsychotic (edit)
Zuclopentixol acetate (edit)
Zuclopentixol decanoate (edit)
Template:Cite book (view source) (protected)
Template:Cite conference (view source) (protected)
Template:Cite journal (view source) (protected)
Template:Documentation (view source) (template editor protected)
Template:Font (view source) (template editor protected)
Template:Hlist/styles.css (view source) (protected)
Template:Main other (view source) (protected)
Template:Navbar (view source) (protected)
Template:No self link (view source) (semi-protected)
Template:No selflink (view source) (semi-protected)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Module:Arguments (view source) (protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Documentation (view source) (template editor protected)
Module:Documentation/config (view source) (template editor protected)
Module:Documentation/styles.css (view source) (template editor protected)
Module:Navbar (view source) (protected)
Module:Navbar/configuration (view source) (protected)
Module:Navbar/styles.css (view source) (protected)
Module:Redirect (view source) (protected)

Return to Template:Pharmacokinetics of long-acting injectable antipsychotics.

Retrieved from "https://en.wikipedia.org/wiki/Template:Pharmacokinetics_of_long-acting_injectable_antipsychotics"